Hyperion DeFi (NASDAQ:HYPD) versus LNG Energy Group (OTCMKTS:MCURF) Head to Head Contrast

Hyperion DeFi (NASDAQ:HYPD) and LNG Energy Group (OTCMKTS:MCURF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares Hyperion DeFi and LNG Energy Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
LNG Energy Group	N/A	N/A	N/A

Valuation and Earnings

This table compares Hyperion DeFi and LNG Energy Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810,000.00	64.38	-$45.31 million	($9.95)	-0.35
LNG Energy Group	N/A	N/A	N/A	N/A	N/A

LNG Energy Group has lower revenue, but higher earnings than Hyperion DeFi.

Insider and Institutional Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Hyperion DeFi and LNG Energy Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	1	1	2.25
LNG Energy Group	0	0	0	0	0.00

Hyperion DeFi presently has a consensus target price of $5.88, indicating a potential upside of 70.78%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, research analysts clearly believe Hyperion DeFi is more favorable than LNG Energy Group.

Summary

Hyperion DeFi beats LNG Energy Group on 7 of the 9 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About LNG Energy Group

Mind Cure Health Inc. engages in the acquisition and development of natural gas production and exploration assets in Latin America. The company was founded in 2008 and is based in Vancouver, Canada.